CA
NZ
UK
AU
IND
US
…
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
uniQure N.V. is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for rare and severe diseases, with programs focused on hemophilia and certain central nervous system disorders. Long-term growth may be driven by successful late-stage trial results, regulatory approvals, strategic partnerships and expansion of in-house AAV manufacturing capabilities. Investors may find the company attractive for potential high-reward, single-dose therapeutic approaches and platform expertise.
The main risk is clinical and regulatory execution combined with manufacturing scale-up and financing needs that could delay or prevent commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -193.34M | -237.13M | -306.56M | -128.26M | 332.81M |
| Net income | -198.97M | -239.56M | -308.48M | -126.79M | 329.59M |
| Selling general administrative | 65.34M | 50.68M | 75.36M | 55.06M | 57.17M |
| Selling and marketing expenses | - | 1.98M | - | - | - |
| Gross profit | 14.41M | 8.79M | 2.21M | 103.14M | 499.03M |
| Reconciled depreciation | 14.76M | 12.64M | 10.04M | 8.54M | 7.30M |
| Ebit | -131.35M | -173.39M | -265.00M | -116.56M | 311.70M |
| Ebitda | -116.59M | -160.75M | -253.10M | -108.02M | 319.00M |
| Depreciation and amortization | 14.76M | 12.64M | 11.90M | 8.54M | 7.30M |
| Non operating income net other | - | - | - | - | 29.66M |
| Operating income | -187.83M | -184.29M | -282.87M | -143.16M | 310.62M |
| Other operating expenses | 203.93M | 197.71M | 298.71M | 249.64M | 213.38M |
| Interest expense | 61.99M | 63.74M | 41.56M | 11.70M | 7.47M |
| Tax provision | 5.63M | 2.43M | -1.32M | -1.47M | 3.22M |
| Interest income | 16.97M | 21.41M | 12.88M | 0.61M | 0.16M |
| Net interest income | -45.03M | -42.33M | -16.39M | -11.10M | -7.31M |
| Income tax expense | 5.63M | 2.43M | 1.92M | -1.47M | 3.22M |
| Total revenue | 16.10M | 27.12M | 15.84M | 106.48M | 524.00M |
| Total operating expenses | 202.24M | 193.09M | 285.09M | 246.30M | 188.41M |
| Cost of revenue | 1.69M | 18.33M | 13.63M | 3.34M | 24.98M |
| Total other income expense net | -5.51M | -52.83M | -23.69M | 14.90M | 22.19M |
| Net income from continuing ops | -198.97M | -239.56M | -228.47M | -126.79M | 329.59M |
| Net income applicable to common shares | - | - | - | -126.79M | 329.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 824.91M | 556.54M | 831.69M | 704.96M | 809.18M |
| Intangible assets | 72.79M | 71.04M | 60.48M | 58.78M | 62.69M |
| Other current assets | 27.58M | 16.89M | 2.65M | 2.81M | 2.67M |
| Total liab | 626.01M | 563.29M | 624.02M | 228.96M | 213.40M |
| Total stockholder equity | 198.90M | -6.75M | 207.67M | 476.01M | 595.78M |
| Other current liab | 33.40M | 29.23M | 29.65M | 56.55M | 28.49M |
| Common stock | 3.69M | 2.94M | 2.88M | 2.84M | 2.80M |
| Capital stock | 3.69M | 2.94M | 2.88M | 2.84M | 2.80M |
| Retained earnings | -1328.94M | -1129.96M | -890.41M | -581.93M | -455.14M |
| Other liab | - | - | - | 18.53M | 46.69M |
| Good will | 25.36M | 22.41M | 26.38M | 25.58M | 27.63M |
| Other assets | - | - | - | 20.59M | 21.54M |
| Cash | 80.24M | 158.93M | 241.36M | 228.01M | 556.26M |
| Total current liabilities | 62.92M | 40.05M | 73.67M | 75.92M | 36.76M |
| Current deferred revenue | 20.49M | - | 29.10M | - | - |
| Net debt | 456.35M | -92.87M | -102.95M | -85.12M | -420.53M |
| Short term debt | 3.86M | 3.60M | 8.34M | 8.38M | 5.77M |
| Short long term debt total | 536.59M | 66.06M | 138.41M | 142.89M | 135.72M |
| Other stockholder equity | 1582.37M | 1173.07M | 1148.75M | 1113.39M | 1076.97M |
| Property plant equipment | - | - | - | 83.26M | 43.51M |
| Total current assets | 655.99M | 390.29M | 651.85M | 476.77M | 628.24M |
| Long term investments | 30.24M | 27.46M | 0.00M | 39.98M | - |
| Net tangible assets | - | - | - | 391.65M | 595.78M |
| Short term investments | 542.30M | 208.59M | 376.53M | 124.83M | - |
| Net receivables | 5.86M | 5.88M | 4.19M | 102.38M | 58.77M |
| Long term debt | 49.70M | 51.32M | 101.75M | 102.79M | 100.96M |
| Inventory | - | 0.00M | 12.02M | 6.92M | 10.54M |
| Accounts payable | 5.17M | 7.23M | 6.59M | 10.98M | 2.50M |
| Accumulated other comprehensive income | -58.22M | -52.80M | -53.55M | -58.29M | -28.86M |
| Common stock total equity | - | - | - | - | 2.80M |
| Retained earnings total equity | - | - | - | - | -455.14M |
| Non currrent assets other | 5.56M | 1.40M | 5.36M | 6.06M | 5.90M |
| Non current assets total | 168.92M | 166.25M | 179.84M | 228.19M | 180.94M |
| Capital lease obligations | 13.69M | 14.74M | 36.66M | 40.10M | 34.76M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -321.18M | 162.97M | -433.46M | -182.73M | -67.39M |
| Change to liabilities | - | - | - | 9.24M | 8.48M |
| Total cashflows from investing activities | -321.62M | - | - | -182.73M | -67.39M |
| Net borrowings | 0.00M | - | - | - | 62.49M |
| Total cash from financing activities | 415.40M | -59.49M | 362.72M | 1.45M | 94.86M |
| Change to operating activities | - | - | - | 3.38M | 9.20M |
| Net income | -198.97M | -239.56M | -308.48M | -126.79M | 329.59M |
| Change in cash | -78.69M | -84.22M | 13.37M | -328.18M | 311.67M |
| Begin period cash flow | 158.93M | 244.54M | 231.17M | 559.35M | 247.68M |
| End period cash flow | 80.24M | 160.33M | 244.54M | 231.17M | 559.35M |
| Total cash from operating activities | -177.96M | -182.73M | -145.93M | -145.06M | 287.96M |
| Issuance of capital stock | 391.90M | 2.12M | 0.86M | 1.45M | 30.90M |
| Depreciation | 14.76M | 12.64M | 11.90M | 8.54M | 7.30M |
| Other cashflows from investing activities | - | 174.66M | - | -163.15M | -49.95M |
| Change to inventory | 0.00M | 2.42M | -6.74M | -6.92M | -6.92M |
| Change to account receivables | -8.60M | -2.24M | -1.32M | -4.08M | -3.96M |
| Sale purchase of stock | - | - | - | - | 32.36M |
| Other cashflows from financing activities | 23.50M | -8.56M | 362.41M | -182.73M | 32.36M |
| Change to netincome | - | - | - | 16.58M | -5.29M |
| Capital expenditures | 0.44M | 3.37M | 7.15M | 17.69M | 17.44M |
| Cash flows other operating | - | - | - | - | -52.12M |
| Cash and cash equivalents changes | - | - | - | - | 315.43M |
| Change in working capital | -6.79M | -3.94M | 81.12M | -43.38M | -50.48M |
| Stock based compensation | 17.68M | 22.26M | 35.09M | 34.20M | 25.64M |
| Other non cash items | -6.23M | 19.50M | 32.51M | -16.16M | -27.29M |
| Free cash flow | -177.96M | -186.10M | -153.08M | -162.75M | 270.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| QURE Uniqure NV |
-2.02 8.77% |
21.01 | - | 27.93 | 160.12 | 9.62 | 126.88 | 1.40 |
| NVO Novo Nordisk A/S |
-1.88 4.46% |
40.30 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.54 1.19% |
542.50 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-27.77 2.98% |
902.90 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew Craig Kapusta | CEO & Exec. Director | 1972 |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 1973 |
| Mr. Pierre Caloz | Chief Operating Officer | NA |
| Dr. Alexander E. Kuta Ph.D. | Exec. VP of Quality & Regulatory Affairs | 1960 |
| Dr. Ricardo Dolmetsch Ph.D. | Pres of R&D | 1969 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | NA |
| Mr. David Cerveny | Chief Legal Officer, Gen. Counsel & Sec. | 1967 |
| Dr. Tamara Tugal Ph.D., MBA | Bus. Devel. Director | NA |
| Ms. Erin Boyer | Chief People & Culture Office | NA |
| Ms. Maria E. Cantor | Chief Corp. Affairs Officer | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.55%
Communication Services
-0.77%
Consumer Cyclical
-1.05%
Consumer Defensive
-0.33%
Energy
-2.55%
Financial Services
-1.62%
Financials
-0.80%
Healthcare
-2.85%
Industrials
-2.47%
Real Estate
-0.85%
Technology
-5.38%
Utilities
-0.83%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+31.04%
Please wait processing your request...